Efficacy and Safety of Oral Weekly Ibandronate in the Treatment of Postmenopausal Osteoporosis

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 10, 2003, Pages 4609-4615

  Cooper, Cyrus ^a   Emkey, Ronald D ^b   McDonald, Robert H ^c   Hawker, Gillian ^d   Bianchi, Gerolamo ^e   Wilson, Katie ^f   Schimmer, Ralph C ^f  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b RADIANT RESEARCH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

^e Ospedale La Colletta   (Italy)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; IBANDRONIC ACID; PLACEBO; VITAMIN D;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; BONE DENSITY; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 0242383409     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-022029     Document Type: Article

References (17)

1. Lombas C, Hakim C, Zanchetta JR 2001 Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 15(Suppl 1):S529 (Abstract M406)
2. Roldán EJA, Negri AL, Gador SA 2001 Short-term compliance to daily alendronate treatment in 1877 patients with osteoporosis. The ECMO study. J Bone Miner Res 16(Suppl 1):S407 (Abstract SU411)
3. Palmisano J, Lewiecki EM, Rosen C, Bookman RS, Vanaman LK, Smith M, Wang L, Yates J 2001 Alendronate 70 mg once weekly and alendronate 10 mg once daily preference study in postmenopausal women with osteoporosis. J Bone Miner Res 16(Suppl 1):S363 (Abstract SU396)
4. Kendler D, Diez-Perez A, Gaines K, Verbuggen N, Melton M 2002 Patient preference of once weekly or daily administration of alendronate (fosamax) for osteoporosis: a randomized cross-over study. Osteoporos Int 13(Suppl 1):S32 (Abstract P92SA)
5. Ravn P, Clemmesen B, Riis BJ, Christiansen C 1996 The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 19:527-533
6. Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schoter KH 1997 Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298-307
7. Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C 2001 Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 16:1871-1878
8. Delmas PD, Recker RR, Stakkestad JA, Chestnut III C, Hoiseth A, Weichselberger A, Huss H, von Stein T, Schimmer R 2002 Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: results from a pivotal phase in study. Osteoporos Int 13(Suppl 1):S15 (Abstract O37)
9. Tanko LB, Felsenberg D, Czerwinski E, Burdeska A, Jonkanski I, Hughes C, Christiansen C, Oral Ibandronate Group 2003 Oral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med 254:159-167
10. Stakkestad JA, Benevolenskaya LI, Stepan JJ, Skag A, Nordby A, Oefjord E, Burdeska A, Jonkanski I, Mahoney P for the Ibandronate Intravenous Study Group 2003 Intravenous ibandronate injections given every 3 months: a novel treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis, in press
11. Smith SY, Recker RR, Hannan M, Müller R, Bauss F 2003 Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32:45-55
12. Monier-Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, Boskey AL, Malluche HH 1999 Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 14:1768-1778
13. Bauss F, Wagner M, Hothorn LH 2002 The total administered dose of ibandronate determines its effect on bone mass and architecture in ovariectomized aged rats. J Rheumatol 29:990-998
14. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora 2nd AC, Kaur A, Thompson DE, Yates J, Orloff JJ 2000 Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1-12
15. Brown J, Kendler D, McClung M, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R 2002 The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71-103-111
16. Tankó LB, McClung MR, Schimmer RC, Mahoney P, Christiansen C 2003 The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 vs. 60 min before breakfast. Bone 32:421-426
17. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282:1344-1352